VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 29, 2007 -- enGene Inc., a privately held biotechnology company developing an innovative approach for the treatment of diabetes called GEMS™-Insulin, announced today that Dr. Anthony T. Cheung, Chief Scientific Officer, will present at the 10th Annual American Society of Gene Therapy Press Conference Meeting, being held in Seattle, WA, June 1, 2007 from 12:15 p.m. to 1:15 p.m. at the Washington State Convention and Trade Center, Room 604. Dr. Cheung will present data on insulin replacement gene therapy for Type 1 diabetes using a novel, integrative, non-viral vector. enGene’s studies show that mice can produce human insulin in a regulated, meal-dependent fashion for over 150 days after a single administration of the GEMS™-Insulin therapy.
